Medication company Viatris (NASDAQ:VTRS) reported Q1 CY2026 results , with sales up 8.1% year on year to $3.52 billion. The company expects the full year’s revenue to be around $14.7 billion, close to ...
Wall Street analysts expect Viatris (VTRS) to post quarterly earnings of $0.52 per share in its upcoming report, which indicates a year-over-year increase of 4%. Revenues are expected to be $3.35 ...